Lin Wu

17.1k total citations · 5 hit papers
231 papers, 5.1k citations indexed

About

Lin Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lin Wu has authored 231 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Oncology, 131 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Lin Wu's work include Lung Cancer Treatments and Mutations (115 papers), Lung Cancer Research Studies (74 papers) and Cancer Immunotherapy and Biomarkers (46 papers). Lin Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (115 papers), Lung Cancer Research Studies (74 papers) and Cancer Immunotherapy and Biomarkers (46 papers). Lin Wu collaborates with scholars based in China, United States and Japan. Lin Wu's co-authors include Arthur P. Grollman, Masaaki Moriya, Julie Tsai, Robert J. Turesky, Ying Cheng, Tony Mok, Yi‐Long Wu, Britta Weber, Boe Sandahl Sørensen and Peter Meldgaard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Lin Wu

205 papers receiving 5.0k citations

Hit Papers

Aristolochic acid and the etiology of endemic (Balkan) ne... 2007 2026 2013 2019 2007 2015 2012 2019 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Aristolochic acid and the etiology of endemic (Balkan) nephropathy
    2007 448 citations Arthur P. Grollman, Shinya Shibutani et al. Proceedings of the National Academy of Sciences profile →
  2. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
    2015 367 citations Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research profile →
  3. Aristolochic acid-associated urothelial cancer in Taiwan
    2012 311 citations Chung‐Hsin Chen, Kathleen G. Dickman et al. Proceedings of the National Academy of Sciences profile →
  4. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    2019 265 citations Yi‐Long Wu, Shun Lü et al. profile →
  5. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lin Wu China 34 2.6k 2.1k 1.4k 1.3k 746 231 5.1k
Florence Dalenc France 33 2.6k 1.0× 1.6k 0.7× 1.3k 0.9× 1.3k 1.0× 428 0.6× 209 4.5k
René Bruno France 35 2.8k 1.0× 1.0k 0.5× 913 0.6× 700 0.5× 668 0.9× 128 4.7k
Junji Tsurutani Japan 40 4.3k 1.6× 2.0k 1.0× 2.3k 1.6× 954 0.7× 1.2k 1.6× 192 6.4k
Marzia Del Re Italy 34 1.6k 0.6× 1.6k 0.8× 1.5k 1.1× 1.3k 1.0× 394 0.5× 167 3.9k
Neeltje Steeghs Netherlands 37 2.8k 1.1× 1.9k 0.9× 1.7k 1.2× 857 0.6× 220 0.3× 242 5.4k
Robert Justice United States 40 2.5k 1.0× 1.7k 0.8× 2.8k 2.0× 871 0.7× 465 0.6× 61 6.4k
Ivana Šestak United Kingdom 36 4.1k 1.6× 1.4k 0.7× 1.4k 1.0× 4.1k 3.1× 369 0.5× 108 7.7k
Francesco Boccardo Italy 39 3.1k 1.2× 2.0k 0.9× 1.4k 1.0× 2.3k 1.7× 335 0.4× 273 6.8k
Agustí Barnadas Spain 34 2.0k 0.8× 789 0.4× 1.6k 1.1× 1.2k 0.9× 238 0.3× 141 4.1k
Henri Roché France 44 6.4k 2.4× 1.8k 0.9× 2.1k 1.5× 3.3k 2.5× 506 0.7× 213 9.0k

Countries citing papers authored by Lin Wu

Since Specialization
Citations

This map shows the geographic impact of Lin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Wu more than expected).

Fields of papers citing papers by Lin Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Wu. The network helps show where Lin Wu may publish in the future.

Co-authorship network of co-authors of Lin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Wu. A scholar is included among the top collaborators of Lin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Wu. Lin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Le, Xiuning, Xiaorong Dong, Herbert H. Loong, et al.. (2025). LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. Annals of Oncology. 36. S1617–S1617.
2.
3.
4.
Sharma, Ashutosh, et al.. (2024). A systematic literature review on the digital platform and its role in the circular economy: State-of-the-art and future research directions. Repository@Nottingham (University of Nottingham). 3. 132–145. 4 indexed citations
5.
Chu, Tianqing, Xiaorong Dong, Huijuan Wang, et al.. (2024). Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors. European Journal of Cancer. 209. 114260–114260. 2 indexed citations
6.
Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations
7.
8.
Liu, Bin, Xingxiang Pu, Lin Wu, et al.. (2024). A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 2534–2534. 1 indexed citations
9.
Zhou, Qing, Lin Wu, Bo Jiang, et al.. (2023). Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.. Journal of Clinical Oncology. 41(16_suppl). 2570–2570. 4 indexed citations
10.
11.
Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →
12.
Zhou, Caicun, Yi Hu, Kejing Ying, et al.. (2023). 540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup. Annals of Oncology. 34. S1680–S1680. 1 indexed citations
13.
Zhou, Qing, Yi‐Long Wu, Jianping Li, et al.. (2023). 658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors. Annals of Oncology. 34. S463–S463. 6 indexed citations
14.
Wang, Qingyi, et al.. (2020). Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 3 indexed citations
15.
Mok, Tony, Yi‐Long Wu, Jin Soo Lee, et al.. (2015). Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research. 21(14). 3196–3203. 367 indexed citations breakdown →
16.
Chen, Chung‐Hsin, Kathleen G. Dickman, Masaaki Moriya, et al.. (2012). Aristolochic acid-associated urothelial cancer in Taiwan. Proceedings of the National Academy of Sciences. 109(21). 8241–8246. 311 indexed citations breakdown →
17.
Ge, Xiaowen, Lin Wu, Weiguo Hu, et al.. (2011). rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia. Clinical Cancer Research. 17(21). 6702–6711. 39 indexed citations
18.
Jordan, Jennifer, Alberto Inga, Kathleen Conway, et al.. (2010). Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. Molecular Cancer Research. 8(5). 701–716. 56 indexed citations
19.
Grollman, Arthur P., Shinya Shibutani, Masaaki Moriya, et al.. (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proceedings of the National Academy of Sciences. 104(29). 12129–12134. 448 indexed citations breakdown →
20.
Wu, Lin, J. Henri Bayle, Brian Elenbaas, Nikola P. Pavletich, & Arnold J. Levine. (1995). Alternatively Spliced Forms in the Carboxy-Terminal Domain of the p53 Protein Regulate Its Ability to Promote Annealing of Complementary Single Strands of Nucleic Acids. Molecular and Cellular Biology. 15(1). 497–504. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Dalenc Breakdown of academic impact, for papers by René Bruno Breakdown of academic impact, for papers by Junji Tsurutani Breakdown of academic impact, for papers by Marzia Del Re Breakdown of academic impact, for papers by Neeltje Steeghs Breakdown of academic impact, for papers by Robert Justice Breakdown of academic impact, for papers by Ivana Šestak Breakdown of academic impact, for papers by Francesco Boccardo Breakdown of academic impact, for papers by Agustí Barnadas Breakdown of academic impact, for papers by Henri Roché
Rankless by CCL
2026